{
  "docId": "019de077-4649-72e2-aa45-017392de211d",
  "docSlug": "8a7a8508ae9537047e1aabcda9819db4",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 27 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 27,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "testimonial",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "KOL = Key Opinion Leader",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-4649-72e2-aa45-017392de211d/21",
  "deckHref": "/decks/019de077-4649-72e2-aa45-017392de211d",
  "deckJsonHref": "/decks/019de077-4649-72e2-aa45-017392de211d.json",
  "deckAnchorHref": "/decks/019de077-4649-72e2-aa45-017392de211d#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.14,
        "x": 0.07,
        "y": 0.58
      },
      "kind": "image",
      "text": "Merit Cudkowicz",
      "attrs": null,
      "subkind": "headshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8e57105-06e5-4357-a54e-b81d053ee643",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.14,
        "x": 0.07,
        "y": 0.2
      },
      "kind": "image",
      "text": "Jeremy M. Shefner",
      "attrs": null,
      "subkind": "headshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da1149f1-d014-44fb-b3cf-51180a56ab49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.24,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "Merit Cudkowicz, M.D., M.Sc. Chair of Neurology and Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08deff19-cc01-4aa5-aa93-2793d22f08ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.24,
        "y": 0.42
      },
      "kind": "paragraph",
      "text": "Jeremy M. Shefner, M.D., Ph.D. Professor of Neurology at the Barrow Neurological Institute, Phoenix, Arizona",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e31bb98d-6c7f-4a4d-81c8-1ace27b2d29d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.24,
        "y": 0.58
      },
      "kind": "quote",
      "text": "\"These exciting long-term results demonstrate how study participants experienced more slowing of progression over time with PrimeC... The need for new treatments for people living with ALS has never been greater. PrimeC has great potential based on its mode of action and the phase 2 trial results, and warrants further evaluation in a Phase 3 trial in an expeditious manner\"",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45f275d7-d8f0-4580-a083-b10c1a868f58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.24,
        "y": 0.2
      },
      "kind": "quote",
      "text": "\"The latest results from the PARADIGM study are incredibly encouraging and provide compelling evidence of PrimeC's potential to significantly benefit people living with ALS... This development brings renewed hope to patients, and I am eagerly looking forward to seeing the program enter Phase 3 to advance the clinical development of this product\"",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e04aa4b2-441c-405f-bf05-64bdfb4b104e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Leading KOLs Perceive PARADIGM’s Results as Highly Compelling",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f17ef721-04e3-4656-84ee-b470646a8c67",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "9424f26e-b5ab-4016-9bfd-c0bf42a7584f",
      "evidence": "Use of expert testimonials to validate clinical trial results.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}